1-19 of 19
Authors: Pierre-Marie Girard
Journal Article
Plasma concentrations of antiretroviral drugs in a successful 4-days-a-week maintenance treatment strategy in HIV-1 patients (ANRS 170-Quatuor trial)
Journal of Antimicrobial Chemotherapy, Volume 79, Issue 6, June 2024, Pages 1380–1384, https://doi.org/10.1093/jac/dkae112
Published: 24 April 2024
Journal Article
Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance
Journal of Antimicrobial Chemotherapy, Volume 78, Issue 6, June 2023, Pages 1510–1521, https://doi.org/10.1093/jac/dkad119
Published: 27 April 2023
Journal Article
Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 7, July 2020, Pages 1961–1968, https://doi.org/10.1093/jac/dkaa091
Published: 19 April 2020
Journal Article
Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads
Journal of Antimicrobial Chemotherapy, Volume 73, Issue 11, November 2018, Pages 3129–3136, https://doi.org/10.1093/jac/dky316
Published: 17 August 2018
Journal Article
Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)
Journal of Antimicrobial Chemotherapy, Volume 73, Issue 6, June 2018, Pages 1672–1676, https://doi.org/10.1093/jac/dky055
Published: 23 March 2018
Journal Article
Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial
Journal of Antimicrobial Chemotherapy, Volume 73, Issue 3, March 2018, Pages 738–747, https://doi.org/10.1093/jac/dkx434
Published: 25 November 2017
Journal Article
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial)
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 8, August 2016, Pages 2252–2261, https://doi.org/10.1093/jac/dkw103
Published: 10 April 2016
Journal Article
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 4, April 2016, Pages 1056–1062, https://doi.org/10.1093/jac/dkv427
Published: 24 December 2015
Journal Article
Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial)
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 2, February 2016, Pages 490–496, https://doi.org/10.1093/jac/dkv369
Published: 14 November 2015
Journal Article
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 1, January 2016, Pages 244–250, https://doi.org/10.1093/jac/dkv323
Published: 19 October 2015
Journal Article
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing Get access
Journal of Antimicrobial Chemotherapy, Volume 70, Issue 5, May 2015, Pages 1503–1506, https://doi.org/10.1093/jac/dku557
Published: 21 January 2015
Journal Article
Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy Get access
Journal of Antimicrobial Chemotherapy, Volume 70, Issue 5, May 2015, Pages 1517–1521, https://doi.org/10.1093/jac/dku532
Published: 11 January 2015
Journal Article
Risk factors for raltegravir resistance development in clinical practice Get access
Journal of Antimicrobial Chemotherapy, Volume 67, Issue 10, October 2012, Pages 2494–2500, https://doi.org/10.1093/jac/dks254
Published: 04 July 2012
Journal Article
Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial Get access
Journal of Antimicrobial Chemotherapy, Volume 65, Issue 11, November 2010, Pages 2436–2444, https://doi.org/10.1093/jac/dkq327
Published: 15 September 2010
Journal Article
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data Get access
Journal of Antimicrobial Chemotherapy, Volume 65, Issue 7, July 2010, Pages 1505–1509, https://doi.org/10.1093/jac/dkq150
Published: 24 May 2010
Journal Article
Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: the Kaledose trial Get access
Journal of Antimicrobial Chemotherapy, Volume 65, Issue 1, January 2010, Pages 125–128, https://doi.org/10.1093/jac/dkp396
Published: 16 November 2009
Journal Article
A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients Get access
Journal of Antimicrobial Chemotherapy, Volume 64, Issue 1, July 2009, Pages 126–134, https://doi.org/10.1093/jac/dkp141
Published: 29 April 2009
Journal Article
Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C Get access
Journal of Antimicrobial Chemotherapy, Volume 63, Issue 3, March 2009, Pages 579–584, https://doi.org/10.1093/jac/dkn531
Published: 23 January 2009
Journal Article
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine Get access
Journal of Antimicrobial Chemotherapy, Volume 61, Issue 6, June 2008, Pages 1344–1347, https://doi.org/10.1093/jac/dkn098
Published: 13 March 2008
